Sorrento Therapeutics, Inc.
SRNE · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $63 | $53 | $40 | $31 |
| % Growth | 18.8% | 32.3% | 27.2% | – |
| Cost of Goods Sold | $33 | $13 | $10 | $12 |
| Gross Profit | $29 | $40 | $30 | $19 |
| % Margin | 46.8% | 75.4% | 75.1% | 61.1% |
| R&D Expenses | $221 | $207 | $111 | $107 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $182 | $197 | $116 | $104 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $130 | $4 | $4 | $4 |
| Operating Expenses | $534 | $408 | $232 | $214 |
| Operating Income | -$504 | -$368 | -$202 | -$195 |
| % Margin | -802.6% | -695.7% | -504% | -621% |
| Other Income/Exp. Net | -$57 | -$94 | -$115 | -$100 |
| Pre-Tax Income | -$562 | -$463 | -$316 | -$360 |
| Tax Expense | -$2 | -$34 | -$2 | -$0 |
| Net Income | -$573 | -$429 | -$298 | -$359 |
| % Margin | -911.6% | -810.9% | -746.4% | -1,142.5% |
| EPS | -1.37 | -1.46 | -1.3 | -2.56 |
| % Growth | 6.2% | -12.3% | 49.2% | – |
| EPS Diluted | -1.37 | -1.46 | -1.3 | -2.56 |
| Weighted Avg Shares Out | 419 | 295 | 230 | 141 |
| Weighted Avg Shares Out Dil | 419 | 295 | 230 | 141 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $9 | $10 | $20 | $36 |
| Depreciation & Amortization | $13 | $16 | $15 | $15 |
| EBITDA | -$540 | -$436 | -$276 | -$308 |
| % Margin | -859.2% | -824.1% | -689.5% | -981.1% |